10-Q: Mangoceuticals Reports Wider Losses Amid Revenue Decline

Mangoceuticals, Inc. reported a significant increase in net loss and a decrease in revenue for the first six months of 2025, raising substantial doubt about its ability to continue as a going concern.

Summary

• Net loss for the six months ended June 30, 2025, increased to $10,255,309, up from $4,758,936 for the same period in 2024.
• Revenues decreased to $277,415 for the six months ended June 30, 2025, compared to $377,258 in the prior year, primarily due to issues with telemedicine platform transition.
• Total operating expenses surged to $10,273,696 for the six months ended June 30, 2025, from $4,753,448 in 2024, driven by higher legal, consulting, salary, and investor relations costs.
• The company's working capital deficit worsened to $1.48 million as of June 30, 2025, from $1.3 million at December 31, 2024.
• An independent registered public accounting firm included an explanatory paragraph in its report, indicating substantial doubt about the company's ability to continue as a going concern.
• Two significant intellectual property/distribution agreements, the Navy Wharf MDA for Diabetinol and the Smokeless Technology Corp. IP Purchase Agreement, were rescinded after being entered into.
• The company settled a lawsuit with Eli Lilly for $20,000 cash and agreed to stop marketing/selling Tirzepatide-based TRIM products on its website.
• Cash and cash equivalents increased to $101,019 as of June 30, 2025, from $58,653 at December 31, 2024, mainly due to financing activities.
• The company continues Phase II clinical trials for patented respiratory illness prevention technology, with studies anticipated to complete in Q3 2025.
• A Master Distribution Agreement for Dermytol (skin brightening) is in place, with operations intended to commence in Q3 2025.

Sentiment

Score: 2

Explanation: The company exhibits significant financial distress with a substantial increase in net loss, a decrease in revenue, and a worsening working capital deficit. The going concern warning, coupled with the rescission of key strategic agreements and high operating expenses, indicates a very challenging outlook despite ongoing capital raising efforts and new IP initiatives.

Positives

• Cash and cash equivalents increased to $101,019 as of June 30, 2025, from $58,653 at December 31, 2024, primarily due to financing activities.
• The company settled a lawsuit with Eli Lilly for a cash payment of $20,000, resolving claims of false advertising.
• Phase II clinical trials for patented respiratory illness prevention technology are ongoing, with results expected in Q3 2025.
• A Master Distribution Agreement for Dermytol, targeting hyperpigmentation and skin brightening, is in place, with operations planned to start in Q3 2025.
• Basic and diluted loss per share improved to $(1.60) for the six months ended June 30, 2025, compared to $(2.90) for the same period in 2024, despite a larger net loss, due to an increased weighted average share count.

Negatives

• Net loss significantly increased to $10,255,309 for the six months ended June 30, 2025, from $4,758,936 in the prior year.
• Revenues decreased to $277,415 for the six months ended June 30, 2025, from $377,258 in 2024, attributed to telemedicine platform transition issues.
• Total operating expenses more than doubled to $10,273,696 for the six months ended June 30, 2025, compared to $4,753,448 in 2024.
• General and administrative expenses rose significantly to $2,787,804 from $1,622,662, due to increased legal, consulting, and acquisition-related costs.
• Salaries and benefits increased to $1,254,941 from $552,314, driven by new management staff and a CEO salary increase.
• Investor relations expenses saw a substantial jump to $1,525,000 from $183,000, reflecting expanded efforts to raise public awareness.
• Stock-based compensation increased significantly to $4,165,924 from $1,313,845, due to greater use of equity-based incentives.
• The working capital deficit worsened to $1.48 million as of June 30, 2025, from $1.3 million at December 31, 2024.
• The company's independent auditor included a going concern explanatory paragraph, indicating substantial doubt about its ability to continue operations for the next 12 months without additional funding.
• The Master Distribution Agreement with Navy Wharf for Diabetinol and the Intellectual Property Purchase Agreement with Smokeless Technology Corp. were both rescinded after being entered into, indicating failed strategic initiatives.
• An arbitration action was brought by Boustead Securities, LLC, claiming over $1,000,000 in fees and warrants, which the company intends to vigorously defend against.

Risks

• Ability to obtain additional funding, the terms of such funding, and dilution caused thereby.
• Limited operating history, limited product production, and limited revenues to date.
• Ability to execute growth strategy, scale operations, and attract customers.
• Effect of pandemics and governmental responses on operations, vendors, customers, and the economy.
• Products are not, and are not expected to be, approved by the U.S. Food and Drug Administration (FDA), lacking the benefit of FDA clinical trial protocols.
• Risk that the FDA may determine compounding of products does not fall within the Section 503A exemption of the FFDCA Act.
• Significant reliance on related party transactions and associated risks.
• Effect of data security breaches, malicious code, and/or hackers.
• Competition and ability to create a well-known brand name.
• Changes in consumer tastes and preferences.
• Material changes and/or terminations of relationships with key parties.
• Significant product returns, product liability, recalls, and litigation associated with tainted products or health issues.
• Ability to innovate, expand offerings, and compete against competitors with greater resources.
• Ability to prevent credit card and payment fraud.
• Risks associated with inflation, interest rates, tariffs, trade wars, economic downturns, geopolitical conflicts (Ukraine/Russian, Israel/Hamas), and other large-scale crises.
• Risk of unauthorized access to confidential information.
• Ability to protect intellectual property and trade secrets, and claims of intellectual property infringement.
• Ability to adequately support future growth.
• Outcome of lawsuits, litigation, regulatory matters, or claims.
• Certain terms in governing documents may prevent a change of control, provide indemnification for officers/directors, limit liability, and allow the board to issue blank check preferred stock.
• Volatile nature of common stock trading price and dilution from current and future security sales.

Future Outlook

The company anticipates needing additional funding to continue operations at current levels and to cover public company costs for the next 12 months. It plans to expand operations organically and through acquisitions in the technology, health, and wellness space, funding permitting. This includes ongoing technology enhancements, further development and marketing of men's health and wellness products, and identifying strategic acquisitions. The Board of Directors has initiated a process to evaluate potential strategic alternatives to maximize shareholder value, including mergers, acquisitions, divestitures, and business combinations, with no set timeline or assurance of a specific outcome.

Management Comments

• "Our plan for the next 12 months is to continue using the same marketing and management strategies and continue providing a quality product with excellent customer service while also seeking to expand our operations organically or through acquisitions as funding and opportunities arise."
• "As our business continues to grow, customer feedback will be integral in making small adjustments to improve products and our overall customer experience."
• "We are headquartered in Dallas, Texas and intend to grow our business both organically and through identifying acquisition targets over the next 12 months in the technology, health and wellness space, funding permitting."
• "Specifically, we plan to continue to make additional and ongoing technology enhancements to our platform, further develop, market and advertise additional mens health and wellness related products on our telemedicine platform, and identify strategic acquisitions that complement our vision."
• "As these opportunities arise, we will determine the best method for financing such acquisitions and growth which may include the issuance of debt instruments, common stock, preferred stock, or a combination thereof, all of which may result in significant dilution to existing shareholders."
• "We may seek additional funding in the future through equity financings, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. We may not be able to obtain financing on acceptable terms or at all."
• "The Company believes this is an ill-willed attempt for Boustead to receive fees in which they are not entitled and that this claim has no basis or merit. The Company intends to vigorously defend itself against this claim with FINRA through arbitration."

Industry Context

The company operates in the growing men's wellness telemedicine sector, focusing on areas like erectile dysfunction, hair loss, testosterone replacement, and weight management. Its strategy involves both compounded products and FDA-approved pharmaceuticals, alongside efforts to acquire and commercialize new intellectual property in related health fields. The rescission of two recent IP/distribution agreements suggests challenges in executing its expansion strategy, while the ongoing Eli Lilly lawsuit highlights regulatory scrutiny in the compounded drug market. The company's reliance on equity and debt financing, coupled with a going concern warning, indicates a challenging capital environment, common for early-stage or rapidly expanding companies in competitive health tech sectors.

Comparison to Industry Standards

• The company's compounded products (Mango ED, Grow, Mojo, Slim) operate under Section 503A of the FFDCA Act, meaning they are not FDA-approved and lack the benefit of FDA clinical trial protocols, unlike many established pharmaceutical products. This contrasts with FDA-approved oral testosterone undecanoate (Prime), which the company also markets.
• The company's reported 96% efficacy by day 90 for Prime (powered by Kyzatrex) in Phase 3 clinical research by Marius Pharmaceuticals positions it favorably against traditional injectable TRTs, which often have lower patient adherence due to invasiveness.
• The rescinded Diabetinol and Smokeless Technology Corp. agreements indicate a struggle to successfully integrate or commercialize new intellectual property, a common challenge for companies attempting rapid diversification or acquisition-led growth in competitive health and wellness markets.
• The company's significant increase in investor relations expenses ($1,525,000 for six months ended June 30, 2025) compared to its revenue ($277,415) is notably high, suggesting a disproportionate focus on capital raising and public awareness relative to revenue generation, which is atypical for mature, profitable industry players.

Management Changes

Corporate Governance

Legal Proceedings

• Eli Lilly and Company filed a complaint alleging false and misleading advertising and promotion for the company's TRIM product (tirzepatide tablets). The lawsuit sought declaratory judgment, injunctions, corrective advertising, and monetary damages. The company settled this lawsuit on June 23, 2025, agreeing to pay Eli Lilly $20,000 in cash and to refrain from marketing and selling its Tirzepatide-based TRIM products on MangoRx.com.
• Boustead Securities, LLC initiated an arbitration action with FINRA on February 18, 2025, claiming over $1,000,000 in cash and warrants for services. The company believes this claim is without merit and intends to vigorously defend itself.

Related Party Transactions

• Epiq Scripts, LLC, which is 52% owned by CEO Jacob Cohen, provides pharmacy and compounding services to the company. The company assigned its rights under Master Services Agreement and Consulting Agreement with Epiq Scripts to Mango & Peaches, with Mango & Peaches assuming obligations.
• Loans from Ronin Equity Partners and Cohen Enterprises, both owned/controlled by CEO Jacob D. Cohen, totaling $187,500 in 2024, were either repaid or sold to a third party.
• A $100,000 promissory note was entered into with The Tiger Cub Trust, controlled by CEO Jacob D. Cohen, bearing 18% interest per annum and convertible into common stock.
• CEO Jacob D. Cohen used his personal credit card for $30,000 in payments to a third-party vendor for company services, outstanding as of June 30, 2025.
• LT Global Practice Management, an entity owned by the wife of CEO Jacob Cohen, provides virtual professionals at rates between $1,800 to $3,500 per full-time virtual professional.
• Mango & Peaches Corp., a subsidiary, issued 4,892,906 shares of its common stock and 100 shares of its Series A Super Majority Voting Preferred Stock to Jacob Cohen, giving him 75.2% voting control over Mango & Peaches.
• CEO Jacob D. Cohen's employment agreement was amended to increase his base yearly compensation to $420,000 (from $360,000), increase monthly office allowance to $10,000 (from $7,500), and increase monthly car allowance to $5,000 (from $2,500). He also received 3,192,906 shares of Mango & Peaches common stock as a bonus.
• COO Amanda Hammer's employment agreement was amended to increase her compensation to $180,000 per year and provide a $15,000 cash bonus.
• An aggregate of 335,000 fully-vested common shares were issued as discretionary bonuses to certain officers and directors, including Jacob D. Cohen, Antonios Isaac, Kenny Myers, Alex Hamilton, and Lorraine D'Alessio.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from ongoing and future equity financings, warrant exercises, and debt conversions. The worsening financial performance and going concern warning pose substantial risk to investment value. The CEO's increased compensation and control over a key subsidiary may raise corporate governance concerns.
• **Employees**: Benefit from increased salaries and equity-based compensation, but the company's going concern status introduces job security uncertainty.
• **Customers**: May experience product availability changes (e.g., discontinuation of Tirzepatide-based TRIM products) and potential impacts on service quality if financial instability affects operations.
• **Suppliers/Creditors**: Face increased risk due to the company's working capital deficit and going concern warning, potentially impacting payment timeliness or ability to fulfill obligations.
• **Regulatory Authorities**: The Eli Lilly settlement and ongoing FDA exemption risks highlight the company's exposure to regulatory scrutiny in the telemedicine and compounded drug space.

Next Steps

• Complete Phase II clinical trials and efficacy studies for patented respiratory illness prevention technology in Q3 2025 to determine commercialization and monetization efforts.
• Prepare marketing and distribution strategy for Dermytol and commence operations under the Master Distribution Agreement in Q3 2025.
• Continue using current marketing and management strategies to provide products and customer service.
• Expand operations organically or through acquisitions in the technology, health, and wellness space, funding permitting.
• Make additional and ongoing technology enhancements to the telemedicine platform.
• Further develop, market, and advertise additional men's health and wellness related products.
• Identify strategic acquisitions that complement the company's vision.
• Determine the best method for financing future acquisitions and growth, potentially through debt instruments, common stock, or preferred stock.
• Vigorously defend against the arbitration action brought by Boustead Securities, LLC.

Key Dates

Recommendation

The company's financial performance is deteriorating significantly, evidenced by a substantial increase in net loss and a decrease in revenue. The explicit 'going concern' warning from auditors indicates severe financial instability and a high risk of business failure without immediate and substantial additional funding. While the company is actively raising capital, this comes at the cost of significant shareholder dilution. The rescission of two major strategic agreements highlights challenges in execution and diversification. Furthermore, the high proportion of expenses allocated to investor relations and stock-based compensation, coupled with substantial increases in CEO compensation amidst declining revenue, raises serious corporate governance concerns. The ongoing arbitration with Boustead adds to legal and financial uncertainty. Given these compounding negative factors, the stock presents a very high risk profile with limited upside potential in the near term.

Keywords

Telemedicine, Men's Wellness, Erectile Dysfunction, Hair Loss, Testosterone Replacement Therapy, Weight Management, Nutraceuticals, Pharmaceutical Products, SEC Filing, 10-Q, Biotechnology, Healthcare Technology